Elizabeth F. Redente
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elizabeth F. Redente has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
- David W. H. Riches
Program in Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado
9 shared publications Alpna Tyagi
4 shared publicationsAlvin M. Malkinson
4 shared publicationsBenjamin L. Edelman
Program in Cell Biology, Department of Pediatrics, National Jewish Health, Denver, USA
4 shared publications- Komal Raina
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences University of Colorado Anschutz Medical Campus Aurora Colorado USA
4 shared publications Kumaraguruparan Ramasamy
4 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Elsevier in Journal of Lipid Research
- Vol. 67 (8)
Intestinal lipase inhibition uncouples diet-induced obesity from MASH by remodeling the hepatic lipidome in mice
- 27 July 2026
- Published by Elsevier in Journal of Lipid Research
- Vol. 67 (8)
Open AccessIntestinal lipase inhibition uncouples diet-induced obesity from MASH by remodeling the hepatic lipidome in mice
- Open Access
- 5 May 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (13)
Pulmonary fibroblast subsets demonstrate differentially enriched signaling pathways during fibrosis resolution and repair
The lungs have a remarkable capacity to undergo homoeostatic repair and regeneration after injury, which often occurs in patients with acute respiratory distress syndrome (ARDS) and in the single-dose bleomycin mouse model. Fibroblasts are critical mediators of fibrotic disease and RNA sequencing has identified significant heterogeneity within pulmonary fibroblast populations. However, the contribution of distinct fibroblast subsets to the repair process has been understudied compared with their role in fibrosis initiation and progression. Therefore, we sought to define the transcriptional landscape of 3 phenotypically defined fibroblast subsets that occupy discrete spatial locations in naive lungs. Using TdTomato-lineage tracing approaches, we identified and interrogated collagen1a1 + ( Col1a1 ) fibroblasts, perilipin 2 + ( Plin2 ) alveolar fibroblasts, and α-smooth muscle actin + ( Acta2 ) myofibroblasts during fibrosis development and resolution after single-dose bleomycin. Quantification of fibroblast numbers showed that all 3 subsets expanded during fibrosis and contracted toward naive levels with resolution. Principal component and gene set enrichment analyses indicate that each subset underwent major transcriptomic shifts during fibrosis development, converging on a similar profibrotic transcriptional profile. However, during resolution, Plin2 + and Acta2 + fibroblasts reverted toward a prefibrotic transcriptional state, whereas Col1a1 + fibroblasts acquired a distinct program that suggests an active role in mediating the repair processes.
- 5 May 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (13)
Open AccessPulmonary fibroblast subsets demonstrate differentially enriched signaling pathways during fibrosis resolution and repair
The lungs have a remarkable capacity to undergo homoeostatic repair and regeneration after injury, which often occurs in patients with acute respiratory distress syndrome (ARDS) and in the single-dose bleomycin mouse model. Fibroblasts are critical mediators of fibrotic disease and RNA sequencing has identified significant heterogeneity within pulmonary fibroblast populations. However, the contribution of distinct fibroblast subsets to the repair process has been understudied compared with their role in fibrosis initiation and progression. Therefore, we sought to define the transcriptional landscape of 3 phenotypically defined fibroblast subsets that occupy discrete spatial locations in naive lungs. Using TdTomato-lineage tracing approaches, we identified and interrogated collagen1a1 + ( Col1a1 ) fibroblasts, perilipin 2 + ( Plin2 ) alveolar fibroblasts, and α-smooth muscle actin + ( Acta2 ) myofibroblasts during fibrosis development and resolution after single-dose bleomycin. Quantification of fibroblast numbers showed that all 3 subsets expanded during fibrosis and contracted toward naive levels with resolution. Principal component and gene set enrichment analyses indicate that each subset underwent major transcriptomic shifts during fibrosis development, converging on a similar profibrotic transcriptional profile. However, during resolution, Plin2 + and Acta2 + fibroblasts reverted toward a prefibrotic transcriptional state, whereas Col1a1 + fibroblasts acquired a distinct program that suggests an active role in mediating the repair processes.
- 22 March 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (7) , 832-834
Fibroblast memory Runx deep: epigenetic recall in pulmonary fibrosis
- 22 March 2026
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 74 (7) , 832-834
Fibroblast memory Runx deep: epigenetic recall in pulmonary fibrosis
- Open Access
- 28 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Conditional BCL-2 Expression in Fibroblasts Promotes Persistent Pulmonary Fibrosis which is Reversible by Therapeutic BCL-2 Inhibition
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease that develops in response to chronic epithelial injury. Unlike injury-induced homeostatic lung repair during which fibroblasts undergo apoptosis and clearance, the lungs of IPF patients continue to accumulate apoptosis-resistant, pro-fibrotic, extracellular matrix-producing fibroblasts. Here, we show that prevention of PDGFRα+ fibroblast apoptosis by conditional BCL-2 expression leads to the emergence and persistence of senescent, pro-fibrotic fibroblasts along with enduring, pathologic fibrotic lung remodeling. Additionally, spatial transcriptomic studies of human IPF lungs confirmed the presence of senescent, BCL-2 expressing α-smooth muscle actin+ myofibroblasts in fibrotic regions. Of translational significance, selective BCL-2 inhibition with ABT-199 in fibrotic mice re-engaged the apoptotic pathway in fibroblasts, reduced senescence, and promoted fibrosis resolution and lung regeneration. Our findings suggest that sustained BCL-2 expression in fibroblasts prevents homeostatic lung repair, drives persistent fibrosis and is a therapeutically relevant target to reverse persistent pulmonary fibrosis.
- 28 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessConditional BCL-2 Expression in Fibroblasts Promotes Persistent Pulmonary Fibrosis which is Reversible by Therapeutic BCL-2 Inhibition
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease that develops in response to chronic epithelial injury. Unlike injury-induced homeostatic lung repair during which fibroblasts undergo apoptosis and clearance, the lungs of IPF patients continue to accumulate apoptosis-resistant, pro-fibrotic, extracellular matrix-producing fibroblasts. Here, we show that prevention of PDGFRα+ fibroblast apoptosis by conditional BCL-2 expression leads to the emergence and persistence of senescent, pro-fibrotic fibroblasts along with enduring, pathologic fibrotic lung remodeling. Additionally, spatial transcriptomic studies of human IPF lungs confirmed the presence of senescent, BCL-2 expressing α-smooth muscle actin+ myofibroblasts in fibrotic regions. Of translational significance, selective BCL-2 inhibition with ABT-199 in fibrotic mice re-engaged the apoptotic pathway in fibroblasts, reduced senescence, and promoted fibrosis resolution and lung regeneration. Our findings suggest that sustained BCL-2 expression in fibroblasts prevents homeostatic lung repair, drives persistent fibrosis and is a therapeutically relevant target to reverse persistent pulmonary fibrosis.
- 3 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (827) , eadr2277
Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling
Aberrant proteostasis in alveolar type 2 epithelial cells (AEC2s) contributes to idiopathic pulmonary fibrosis (IPF), but the role of the ubiquitin-proteasome system (UPS) is unclear. Here, we show that UPS disruption in AEC2s amplifies profibrotic signaling to macrophages through macrophage migration inhibitory factor (MIF) family proteins in several models. Modeling UPS disruption with an AEC2-specific cullin 3 ( Cul3 ) deletion produced spontaneous fibrosis in a physiological aging mouse model and exacerbated fibrosis in the bleomycin-induced lung injury model. This was accompanied by expansion of transitional epithelial states and increased MIF and MIF-2 in lung tissue and bronchoalveolar lavage fluid (BALF) in the model. Global or conditional AEC2-specific deletions of Mif or Mif-2 attenuated fibrosis in the bleomycin-treated mouse model, as did conditional deletions of Cd74 , the cognate receptor for MIF and MIF-2, in C-X3-C motif chemokine receptor 1 ( Cx3cr1 )–expressing and platelet factor 4 ( Pf4 )–expressing cells. Pharmacological inhibition of MIF attenuated fibrosis in bleomycin-treated and transforming growth factor–β1 ( TGFB1 ) transgenic mouse models and in ex vivo human precision-cut lung slices treated with fibrotic cocktail. In study participants with IPF, BALF MIF was elevated compared with that in study participants without IPF. In participants with IPF, BALF MIF greater than 4000 picograms per milliliter was associated with increased mortality compared with participants with IPF with lower MIF. Together, these findings define a UPS-sensitive epithelial-macrophage signaling connection and identify MIF-CD74 cross-talk as a potential therapeutic target in fibrotic lung disease.
- 3 December 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (827) , eadr2277
Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling
Aberrant proteostasis in alveolar type 2 epithelial cells (AEC2s) contributes to idiopathic pulmonary fibrosis (IPF), but the role of the ubiquitin-proteasome system (UPS) is unclear. Here, we show that UPS disruption in AEC2s amplifies profibrotic signaling to macrophages through macrophage migration inhibitory factor (MIF) family proteins in several models. Modeling UPS disruption with an AEC2-specific cullin 3 ( Cul3 ) deletion produced spontaneous fibrosis in a physiological aging mouse model and exacerbated fibrosis in the bleomycin-induced lung injury model. This was accompanied by expansion of transitional epithelial states and increased MIF and MIF-2 in lung tissue and bronchoalveolar lavage fluid (BALF) in the model. Global or conditional AEC2-specific deletions of Mif or Mif-2 attenuated fibrosis in the bleomycin-treated mouse model, as did conditional deletions of Cd74 , the cognate receptor for MIF and MIF-2, in C-X3-C motif chemokine receptor 1 ( Cx3cr1 )–expressing and platelet factor 4 ( Pf4 )–expressing cells. Pharmacological inhibition of MIF attenuated fibrosis in bleomycin-treated and transforming growth factor–β1 ( TGFB1 ) transgenic mouse models and in ex vivo human precision-cut lung slices treated with fibrotic cocktail. In study participants with IPF, BALF MIF was elevated compared with that in study participants without IPF. In participants with IPF, BALF MIF greater than 4000 picograms per milliliter was associated with increased mortality compared with participants with IPF with lower MIF. Together, these findings define a UPS-sensitive epithelial-macrophage signaling connection and identify MIF-CD74 cross-talk as a potential therapeutic target in fibrotic lung disease.
- 1 November 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 73 (5) , 653-667
Pulmonary Fibrosis—Focusing on the Future: Aspen Lung Conference 2024 Summary
As medical and scientific communities, we have enjoyed exciting advances in our mechanistic understanding, diagnosis, and therapy of different types of lung fibrosis. However, much still needs to be learned as we are challenged to make earlier diagnoses; improve our ability to assess active disease and risks for disease progression; advance our understanding of the complex interplay of molecular, genetic, and cellular cross-talk processes that underly the disease; and develop transformative therapeutic options to treat and prevent progressive lung fibrosis. Elucidating cellular phenotypes, function and signaling, and the interplay with matrices and aspects of mechanobiology has the potential to help us identify future targets and even reprogram or rebuild a damaged lung. Key to potential future opportunities will be understanding what aspects of fibrogenesis can be prevented or reversed. Bringing together a group of respected medical and scientific thought leaders, the 66th Annual Thomas L. Petty Aspen Lung Conference was titled “Pulmonary Fibrosis—Focusing on the Future.” The conference topics included concepts and technologies for identification of early disease and progression using imaging and -omics approaches, identifying and understanding cellular phenotypes and their function, and cross-talk between different cell types, matrices, and matrix receptors. A central theme throughout was the integration of these scientific advances to advance novel targets for therapy, including aspects of reprogramming and rebuilding a damaged lung. The conference provided a forum for discussion, debate, and exchange of ideas with leaders and trainees in the field with the goal to help advance our shared mission of preventing and curing pulmonary fibrotic disease.
- 1 November 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 73 (5) , 653-667
Pulmonary Fibrosis—Focusing on the Future: Aspen Lung Conference 2024 Summary
As medical and scientific communities, we have enjoyed exciting advances in our mechanistic understanding, diagnosis, and therapy of different types of lung fibrosis. However, much still needs to be learned as we are challenged to make earlier diagnoses; improve our ability to assess active disease and risks for disease progression; advance our understanding of the complex interplay of molecular, genetic, and cellular cross-talk processes that underly the disease; and develop transformative therapeutic options to treat and prevent progressive lung fibrosis. Elucidating cellular phenotypes, function and signaling, and the interplay with matrices and aspects of mechanobiology has the potential to help us identify future targets and even reprogram or rebuild a damaged lung. Key to potential future opportunities will be understanding what aspects of fibrogenesis can be prevented or reversed. Bringing together a group of respected medical and scientific thought leaders, the 66th Annual Thomas L. Petty Aspen Lung Conference was titled “Pulmonary Fibrosis—Focusing on the Future.” The conference topics included concepts and technologies for identification of early disease and progression using imaging and -omics approaches, identifying and understanding cellular phenotypes and their function, and cross-talk between different cell types, matrices, and matrix receptors. A central theme throughout was the integration of these scientific advances to advance novel targets for therapy, including aspects of reprogramming and rebuilding a damaged lung. The conference provided a forum for discussion, debate, and exchange of ideas with leaders and trainees in the field with the goal to help advance our shared mission of preventing and curing pulmonary fibrotic disease.
- Open Access
- 9 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (22)
Pathogenic expansion: fibroblast proliferation fuels fibrosis
Pulmonary fibrosis, an unrelenting disease of lung scarring, has been associated with the expansion of a profibrotic fibroblast population and extensive extracellular matrix deposition. In this issue, Molina and colleagues provide foundational mechanistic evidence that fibroblast proliferation itself is a critical driver of fibrosis. Using lineage tracing in preclinical fibrosis models, the authors showed that naive Scube2 + alveolar fibroblasts underwent a profibrotic phenotypic switch prior to proliferating within areas of fibrotic remodeling. Induction of apoptosis via Esco2 deletion or directly preventing proliferation via Ect2 deletion in these fibroblasts attenuated fibrosis. Complementary analyses on explanted human lung tissue confirmed translational relevance, collectively providing compelling evidence for the importance of fibroblast proliferation in fibrotic disease.
- 9 September 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (22)
Open AccessPathogenic expansion: fibroblast proliferation fuels fibrosis
Pulmonary fibrosis, an unrelenting disease of lung scarring, has been associated with the expansion of a profibrotic fibroblast population and extensive extracellular matrix deposition. In this issue, Molina and colleagues provide foundational mechanistic evidence that fibroblast proliferation itself is a critical driver of fibrosis. Using lineage tracing in preclinical fibrosis models, the authors showed that naive Scube2 + alveolar fibroblasts underwent a profibrotic phenotypic switch prior to proliferating within areas of fibrotic remodeling. Induction of apoptosis via Esco2 deletion or directly preventing proliferation via Ect2 deletion in these fibroblasts attenuated fibrosis. Complementary analyses on explanted human lung tissue confirmed translational relevance, collectively providing compelling evidence for the importance of fibroblast proliferation in fibrotic disease.
- 1 August 2025
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 46 (04) , 295-297
Bridging Bench to the Bedside: The Imperative of Preclinical and Translational Research in Pulmonary Medicine
Despite decades of clinical advancement, many acute, chronic, and progressive lung diseases, such as acute lung injury (ALI), idiopathic pulmonary fibrosis (IPF), lymphangioleiomyomatosis (LAM), and asthma, remain incurable with limited therapeutic options and high morbidity and mortality. Collectively, asthma, IPF, ALI, and LAM impose an annual health care burden exceeding US$100 billion worldwide, reflecting high hospitalization and treatment costs and underscoring the urgent need for basic and translational research to develop effective therapies that reduce morbidity, mortality, and economic impact. The pathophysiology of these diseases is highly complex, driven by the interplay of aging, environmental exposures, genetic susceptibility, cellular heterogeneity, dynamic tissue remodeling, and immune dysregulation. Therefore, it is imperative to investigate the mechanistic underpinnings of disease pathobiology beyond clinical observations and patient-based studies alone. In this context, preclinical and translational research using advanced in vitro cell and ex vivo tissue systems, animal models, and multiomics technologies serves not merely as a complementary approach but rather the essential foundation for translating fundamental discoveries into novel clinical interventions. This issue of Seminars in Respiratory and Critical Care Medicine brings together a collection of articles that collectively underscore the indispensable role of basic and translational science in shaping the future of pulmonary medicine. From dissecting the molecular underpinnings of fibroblast activation in IPF to unraveling the immune-regulatory functions of T cells and macrophages in lung injury and repair in basic translational research. Preclinical models of pulmonary fibrosis are indispensable for dissecting the cellular and molecular mechanisms driving fibrotic lung remodeling, enabling the identification and validation of therapeutic targets that cannot be fully explored through patient studies alone. The bleomycin-induced lung injury model remains the most widely used and well-characterized experimental system for studying pulmonary fibrosis. As reviewed by Brazee et al, this model offers a reproducible framework to investigate the temporal progression of fibrosis from acute inflammation to fibroproliferation followed by spontaneous resolution.[1] While it does not fully recapitulate the histopathological hallmarks of IPF, such as honeycomb cysts and fibroblastic foci, it has nonetheless been instrumental in the preclinical validation of interstitial lung diseases' FDA-approved therapies pirfenidone and nintedanib. Importantly, refinements to the bleomycin model, such as repetitive dosing, use of aged mice, targeted genetic mutations, and combination injury approaches, have enhanced its translational relevance. These adaptations allow researchers to mimic persistent and progressive fibrosis, better reflecting the clinical trajectory of IPF. Moreover, the bleomycin model's flexibility enables interrogation of the time after injury, sex, strain, microbiome, and environmental influences on disease susceptibility and therapeutic response. It is only in understanding and capitalizing on these insights that will allow for better therapeutic development and the identification of novel disease-based biomarkers as highlighted by Schott et al.[2] Additionally, utilizing the correct in vivo models remains critical for developing personalized treatment strategies and for understanding disease heterogeneity. Singh et al provide a comprehensive analysis of fibroblast heterogeneity and activation in pulmonary fibrosis.[3] Their work highlights the diverse cellular origins of myofibroblasts, including resident alveolar fibroblasts, and the transcriptional programs that govern their differentiation and persistence during fibrosis. The identification of key regulators, such as TGF-β, PDGF, Wnt ligands, and transcription factors like SMADs, STATs, WT1, and Sox9, offers promising opportunities as therapeutic targets to halt or reverse the profibrotic pathogenesis associated with these critical cells. Additionally, these findings underscore the value of state-of-the-art technologies, including lineage tracing, single-cell RNA sequencing, and spatial transcriptomics, which have allowed researchers to follow and determine mesenchymal cell fate decisions, differentiation pathways, and intercellular communication within the fibrotic niche. Such technologies, when applied to animal models and in vitro human cells and ex vivo human tissue samples, allow research to bridge the gap between molecular discovery and clinical application, enabling the development of targeted antifibrotic therapies. The complexity of the immune system and its role in pulmonary diseases has been a challenge to study, with exact homologs of human immune cell populations not always being present within murine lungs. However, the importance and contribution of the immune system to every stage of pulmonary disease: Initiation, development, progression, and eventual resolution cannot be underestimated. The article by Pastore et al delves into the immunoregulatory functions of T regulatory cells (Tregs) in airway and ILDs.[4] Their work reveals how Tregs adapt to microenvironmental cues, acquiring phenotypes that either suppress inflammation or contribute to pathogenic remodeling. In asthma, for instance, Tregs can be skewed toward a Th2-like profile, undermining their suppressive capacity and exacerbating disease. Aging, hormonal changes, and genetic polymorphisms further modulate Treg function, highlighting the need for age- and sex-specific therapeutic approaches. Complementing this, Bersie and McCubbrey discuss and explore the heterogeneity of lung phagocytes and their role in clearing apoptotic cells during a process known as efferocytosis.[5] Efficient efferocytosis by alveolar macrophages, interstitial macrophages, dendritic cells, epithelial...
- 1 August 2025
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 46 (04) , 295-297
Bridging Bench to the Bedside: The Imperative of Preclinical and Translational Research in Pulmonary Medicine
Despite decades of clinical advancement, many acute, chronic, and progressive lung diseases, such as acute lung injury (ALI), idiopathic pulmonary fibrosis (IPF), lymphangioleiomyomatosis (LAM), and asthma, remain incurable with limited therapeutic options and high morbidity and mortality. Collectively, asthma, IPF, ALI, and LAM impose an annual health care burden exceeding US$100 billion worldwide, reflecting high hospitalization and treatment costs and underscoring the urgent need for basic and translational research to develop effective therapies that reduce morbidity, mortality, and economic impact. The pathophysiology of these diseases is highly complex, driven by the interplay of aging, environmental exposures, genetic susceptibility, cellular heterogeneity, dynamic tissue remodeling, and immune dysregulation. Therefore, it is imperative to investigate the mechanistic underpinnings of disease pathobiology beyond clinical observations and patient-based studies alone. In this context, preclinical and translational research using advanced in vitro cell and ex vivo tissue systems, animal models, and multiomics technologies serves not merely as a complementary approach but rather the essential foundation for translating fundamental discoveries into novel clinical interventions. This issue of Seminars in Respiratory and Critical Care Medicine brings together a collection of articles that collectively underscore the indispensable role of basic and translational science in shaping the future of pulmonary medicine. From dissecting the molecular underpinnings of fibroblast activation in IPF to unraveling the immune-regulatory functions of T cells and macrophages in lung injury and repair in basic translational research. Preclinical models of pulmonary fibrosis are indispensable for dissecting the cellular and molecular mechanisms driving fibrotic lung remodeling, enabling the identification and validation of therapeutic targets that cannot be fully explored through patient studies alone. The bleomycin-induced lung injury model remains the most widely used and well-characterized experimental system for studying pulmonary fibrosis. As reviewed by Brazee et al, this model offers a reproducible framework to investigate the temporal progression of fibrosis from acute inflammation to fibroproliferation followed by spontaneous resolution.[1] While it does not fully recapitulate the histopathological hallmarks of IPF, such as honeycomb cysts and fibroblastic foci, it has nonetheless been instrumental in the preclinical validation of interstitial lung diseases' FDA-approved therapies pirfenidone and nintedanib. Importantly, refinements to the bleomycin model, such as repetitive dosing, use of aged mice, targeted genetic mutations, and combination injury approaches, have enhanced its translational relevance. These adaptations allow researchers to mimic persistent and progressive fibrosis, better reflecting the clinical trajectory of IPF. Moreover, the bleomycin model's flexibility enables interrogation of the time after injury, sex, strain, microbiome, and environmental influences on disease susceptibility and therapeutic response. It is only in understanding and capitalizing on these insights that will allow for better therapeutic development and the identification of novel disease-based biomarkers as highlighted by Schott et al.[2] Additionally, utilizing the correct in vivo models remains critical for developing personalized treatment strategies and for understanding disease heterogeneity. Singh et al provide a comprehensive analysis of fibroblast heterogeneity and activation in pulmonary fibrosis.[3] Their work highlights the diverse cellular origins of myofibroblasts, including resident alveolar fibroblasts, and the transcriptional programs that govern their differentiation and persistence during fibrosis. The identification of key regulators, such as TGF-β, PDGF, Wnt ligands, and transcription factors like SMADs, STATs, WT1, and Sox9, offers promising opportunities as therapeutic targets to halt or reverse the profibrotic pathogenesis associated with these critical cells. Additionally, these findings underscore the value of state-of-the-art technologies, including lineage tracing, single-cell RNA sequencing, and spatial transcriptomics, which have allowed researchers to follow and determine mesenchymal cell fate decisions, differentiation pathways, and intercellular communication within the fibrotic niche. Such technologies, when applied to animal models and in vitro human cells and ex vivo human tissue samples, allow research to bridge the gap between molecular discovery and clinical application, enabling the development of targeted antifibrotic therapies. The complexity of the immune system and its role in pulmonary diseases has been a challenge to study, with exact homologs of human immune cell populations not always being present within murine lungs. However, the importance and contribution of the immune system to every stage of pulmonary disease: Initiation, development, progression, and eventual resolution cannot be underestimated. The article by Pastore et al delves into the immunoregulatory functions of T regulatory cells (Tregs) in airway and ILDs.[4] Their work reveals how Tregs adapt to microenvironmental cues, acquiring phenotypes that either suppress inflammation or contribute to pathogenic remodeling. In asthma, for instance, Tregs can be skewed toward a Th2-like profile, undermining their suppressive capacity and exacerbating disease. Aging, hormonal changes, and genetic polymorphisms further modulate Treg function, highlighting the need for age- and sex-specific therapeutic approaches. Complementing this, Bersie and McCubbrey discuss and explore the heterogeneity of lung phagocytes and their role in clearing apoptotic cells during a process known as efferocytosis.[5] Efficient efferocytosis by alveolar macrophages, interstitial macrophages, dendritic cells, epithelial...
- Open Access
- 1 August 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (8) , 1346-1368
Addressing Sex as a Biological Variable in Preclinical Models of Lung Disease: An Official American Thoracic Society Research Statement
Background: Pulmonary diseases have sex-specific predilections across the lifespan. The rigor of preclinical research is paramount to ensure the reproducibility and applicability of findings to clinical studies. The overarching goal was to identify current research gaps and the need for consideration of sex as a biological variable (SABV) in preclinical pulmonary research. The objective was to provide a roadmap and the best standards to incorporate and investigate the role of biological sex in preclinical models of lung diseases. Methods: A multidisciplinary working group of 17 international investigators from the American Thoracic Society Assembly on Allergy, Immunology, and Inflammation, external content experts, and researchers engaged in lung basic and translational research. They reviewed the literature, identified critical knowledge gaps, and provided recommendations. Results: The research statement provides an updated summary of the currently available evidence on the standards of SABV research in preclinical models and then offers specific research recommendations focused on the needs of researchers in the pulmonary field. The statement identifies knowledge gaps and develops guidance for experimental design and key considerations for incorporating SABV in two major topic areas: 1) in vivo; and 2) in vitro models. Furthermore, the group developed a checklist to guide researchers in including SABV in preclinical studies. Conclusions: This statement provides a roadmap for the investigation of SABV in preclinical models. This will increase the applicability of findings to both sexes, uncover sex-biased mechanisms in lung diseases, and identify novel therapeutic targets.
- 1 August 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (8) , 1346-1368
Open AccessAddressing Sex as a Biological Variable in Preclinical Models of Lung Disease: An Official American Thoracic Society Research Statement
Background: Pulmonary diseases have sex-specific predilections across the lifespan. The rigor of preclinical research is paramount to ensure the reproducibility and applicability of findings to clinical studies. The overarching goal was to identify current research gaps and the need for consideration of sex as a biological variable (SABV) in preclinical pulmonary research. The objective was to provide a roadmap and the best standards to incorporate and investigate the role of biological sex in preclinical models of lung diseases. Methods: A multidisciplinary working group of 17 international investigators from the American Thoracic Society Assembly on Allergy, Immunology, and Inflammation, external content experts, and researchers engaged in lung basic and translational research. They reviewed the literature, identified critical knowledge gaps, and provided recommendations. Results: The research statement provides an updated summary of the currently available evidence on the standards of SABV research in preclinical models and then offers specific research recommendations focused on the needs of researchers in the pulmonary field. The statement identifies knowledge gaps and develops guidance for experimental design and key considerations for incorporating SABV in two major topic areas: 1) in vivo; and 2) in vitro models. Furthermore, the group developed a checklist to guide researchers in including SABV in preclinical studies. Conclusions: This statement provides a roadmap for the investigation of SABV in preclinical models. This will increase the applicability of findings to both sexes, uncover sex-biased mechanisms in lung diseases, and identify novel therapeutic targets.
- Top Cited PapersOpen Access
- 2 January 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (1)
Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium
Idiopathic pulmonary fibrosis (IPF) is etiologically complex, with well-documented genetic and nongenetic origins. In this Review, we speculate that the development of IPF requires two hits: the first establishes a vulnerable bronchoalveolar epithelium, and the second triggers mechanisms that reprogram distal epithelia to initiate and perpetuate a profibrotic phenotype. While vulnerability of the bronchoalveolar epithelia is most often driven by common or rare genetic variants, subsequent injury of the bronchoalveolar epithelia results in persistent changes in cell biology that disrupt tissue homeostasis and activate fibroblasts. The dynamic biology of IPF can best be contextualized etiologically and temporally, including stages of vulnerability, early disease, and persistent and progressive lung fibrosis. These dimensions of IPF highlight critical mechanisms that adversely disrupt epithelial function, activate fibroblasts, and lead to lung remodeling. Together with better recognition of early disease, this conceptual approach should lead to the development of novel therapeutics directed at the etiologic and temporal drivers of lung fibrosis that will ultimately transform the care of patients with IPF from palliative to curative.
- 2 January 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (1)
Top Cited PapersOpen AccessProgressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium
Idiopathic pulmonary fibrosis (IPF) is etiologically complex, with well-documented genetic and nongenetic origins. In this Review, we speculate that the development of IPF requires two hits: the first establishes a vulnerable bronchoalveolar epithelium, and the second triggers mechanisms that reprogram distal epithelia to initiate and perpetuate a profibrotic phenotype. While vulnerability of the bronchoalveolar epithelia is most often driven by common or rare genetic variants, subsequent injury of the bronchoalveolar epithelia results in persistent changes in cell biology that disrupt tissue homeostasis and activate fibroblasts. The dynamic biology of IPF can best be contextualized etiologically and temporally, including stages of vulnerability, early disease, and persistent and progressive lung fibrosis. These dimensions of IPF highlight critical mechanisms that adversely disrupt epithelial function, activate fibroblasts, and lead to lung remodeling. Together with better recognition of early disease, this conceptual approach should lead to the development of novel therapeutics directed at the etiologic and temporal drivers of lung fibrosis that will ultimately transform the care of patients with IPF from palliative to curative.